Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children

NCT07020052 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
33
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology